This is a preview of updates coming to the Technical Bulletin's website in April 2026. Return to current site.
Read more about the modernization release schedule in this announcement.
Comment via the yellow feedback button in the lower right hand corner of the page. Contact the NLM Help Desk with any questions or concerns.
This is archived content.
Links may have become inactive over time. Visit Archive-It to find the original published layout.
New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI)
New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI). NLM Tech Bull. 2011 Sep-Oct;(382):e15.
October 25, 2011 [posted]
The National Heart, Lung, and Blood Institute (NHLBI) issued a new Clinical Alert on October 21, 2011:
NHLBI has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.
Links to Clinical Alerts/Advisories can also be found from these NLM® Web sites:
- A complete list of all Clinical Alerts/Advisories is available from the NIH Clinical Alerts and Advisories page on the NLM Web site.
- MedlinePlus® features Clinical Alerts/Advisories as NIH Press Releases on the appropriate Health Topics page(s).
- PubMed®, the NLM Gateway and ClinicalTrials.gov each have access points to the Clinical Alerts/Advisories.